UK: Genericsweb Analyses Opportunity For Generic Docetaxel

Last Updated: 14 February 2011
Article by John Zhicong He

Docetaxel, a taxane type anticancer drug, developed by Sanofi-Aventis and marketed under the brand name of Taxotere, lost its molecule patent protections in US and major European jurisdictions last month. Docetaxel is considered the largest oncology product ever developed with global market value at $3 billion in 2009. It is also arguably predicted that Docetaxel will lead the taxane market for the next decade since Docetaxel represents the reaching of a plateau stage in taxane development and further R&D in taxanes is unlikely to be cost effective. The loss of protection on the molecule patent will inevitably attract significant generic activity in the months and years to come. This month's Drug in Focus will analyse the patent landscape surrounding Docetaxel based on information disclosed in GenericsWeb's Core Pipeline Selector report.

Table 1: Docetaxel General Information

The Docetaxel General Information (Table 1) extracted from the Pipeline Selector report discloses general product information in relation to Taxotere. Docetaxel can be considered a relatively versatile anticancer drug, being indicated for breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, head and neck cancer and ovarian cancer, in some cases in combination with other anticancer agents. The Taxotere products are supplied in single vial and double vial systems for intravascular injection. The single vial system contains Docetaxel as the active ingredient, polysorbate and about 50% absolute ethanol in one vial, while the double vial system has Docetaxel and polysorbate in one vial, and 13% ethanol in water for injection as diluent in a separate vial. The double vial system is available in most major markets including the US, Europe, Canada and Australia while the single vial system is only available in the European continent.

Table 2: Docetaxel Key Patent Indicator

The Docetaxel Key Patent Indicator (KPI) (Table 2) identifies four patent families as being of significant commercial relevance to the Taxotere products. The patent family with priority number FR8610400A protects the Docetaxel molecule per se. The patent expiry data for this family shows that the Docetaxel molecule firstly lost protection in Spain in 2007 due to a rejection of a Supplementary Protection Certificate (SPC) application. Canadian patent protection for the Docetaxel molecule also ended in 2007 as the normal term expired, and there is no patent term extension provisions in Canada. In contrast, the US and other major European equivalents have longer patent protection due to granted PTE or SPCs in these jurisdictions. Patent, US4814470 expired last month after the term of the 6 month paediatric extension, in addition to the USC section 156 PTE of 1035 days. SPCs on the European equivalents in this family also expired last month in major territories. Similarly, a section 70 PTE in Australia allows the Docetaxel molecule patent to be in force until February 2011 due to a later TGA approval date.

In addition to the molecule patent family, the KPI identifies two formulation patent families. It is well known that taxane compounds generally have low water solubility for clinical use. Traditionally, ethanol and surfactant, such as polyethoxylated castor oil, were used to stabilise the active ingredient in preparation of taxane formulations. The FR9108527A patent family specifically claims taxane compositions comprising surfactants and a much reduced or eliminated ethanol content. Patents in this family expire in July 2012 in Australia, Canada, and most major European countries. The normal term of three US patents, US5698582, US5714512 and US5750561 are extended to January 2013 based on paediatric extensions. The last US member US5403858 expires on 23 August 2013 but is not Orange book listed implying that it does not protect the commercial Taxotere product (however this should be verified). The FR9214501A family protects a twin vial system which contains the active ingredient concentrate in one part and a diluent containing an agent, e.g. ethanol that prevents gelling upon dilution of the concentrate in the other. Patents in this family generally expire in November 2013 except the US equivalent which expires in May 2014 after accounting for the paediatric extension.

Both of these formulation patent families appear to protect only the twin vial system and are likely to result in some difficulty in developing bioequivalent generic versions of Taxotere expiry 2-3 years after molecule patent expiry. Noteworthy is that the Pipeline Selector Litigation Alert identifies cases in relation to patents in these two families, suggesting that they are indeed problematic to generic developers, and would perhaps have been difficult to circumvent. In some cases the asserted patent claims have been found invalid or unenforceable, hence it is important to review any litigation alerts fully to understand the scope and enforceability with respect to generic products. In Europe, however, an opportunity exists to launch the single vial system upon expiry of the molecule patent, as the commercial Taxotere does not appear to be protected by any of these later key formulation patents.

A further family listed in the KPI relates to use of Docetaxel in combination with other therapeutic agents, such as topoisomerase poisons, alkylating agents, antibiotics, platinum complexes and others. Patents in this family will expire in the US in May 2015 and in November 2013 in most other countries. However caution should be exercised as there is a related European patent filing which also encompasses use of Docetaxel having an expiry date of March 2022, which seems very pertinent to some of the current approved indications for the Taxotere product. This family may therefore be problematic for generic companies seeking to launch a generic Docetaxel product with exactly the same indications as those for Taxotere and some modification of the indications may be required to avoid infringement.

Data exclusivity (DE) is another important weapon for pharmaceutical innovators to protect their R&D Investment. Information related to this can also be found in the Pipeline Selector report for Docetaxel which shows that, with the exception of some use and paediatric use exclusivity in the US, there is no current protection in major markets that would significantly constrain generic competition.

The Pipeline Selector report also discloses marketing authorisations in relation to the Docetaxel product in certain countries, both branded and generic (Table 3). It can be seen from the news articles that Actavis and other generic companies have started to sell generic Docetaxel single vial products in Europe. Limited investigation shows that these formulations contain higher levels of ethanol and therefore circumvent the key formulation patents. Several other generic manufactures also obtained market authorisations for their generic Docetaxel products in European countries. In Australia, Interpharm has obtained marketing authorisation for a generic Docetaxel product. Interestingly, no generic Docetaxel is identified as available in Canada. Presumably, the litigation case around CA2150576, CA2102777 and CA2102778 has resulted in an extended monopoly of the Taxotere product in this market. Generic Docetaxel products are not yet available in the US market however, several tentative approvals have been identified and a total of 18 Drug Master Files (DMF) in relation to Docetaxel have been filed, suggesting that this product will go generic once any outstanding litigation has been dealt with.

Table 3: Regulatory data for Docetaxel

Figure 1 shows the patent filing trend for patents in relation to Docetaxel, based on a comprehensive set of patent publications for the Docetaxel product as found in the corresponding pipeline developer report. This clearly shows that the number of patent families filed has dramatically increased since 1996 – the launch of the Taxotere product. This is a typical pattern showing a substantial number of generic players are interested in Docetaxel and started their R&D on the drug as early as the launch of the Taxotere product. This can be further confirmed with Figure 2, where the innovator still takes the number one position on the top applicant list in regards to Docetaxel patent applications – but only filing 8% of patents relevant to the drug.  Figure 1 also indicates that the patenting activity relating to this drug heavily focuses on formulations, with around 40% of the total patent families falling into this category. Presumably, those generic players also consider that the formulation in the Taxotere product is a tough part to circumvent and invest in their own IP to protect their efforts and set barriers to other generic competitors in this field. Readers should be aware that this number of patents may also include patents in relation to Paclitaxel, due to the fact that these two popular taxane drugs are jointly the subject of many patents. Generic players are therefore strongly advised that a significant amount of attention should be paid to identifying and evaluating such patents to ensure that their product does comprise of any protected formulation or active ingredient at the time of commercialisation. This can be achieved by subscribing to GenericsWeb's Pipeline Developer report for a comprehensive review of the patent landscape surrounding the Docetaxel product.

Figure 1: Docetaxel Patent Filing Trends

Figure 2: Docetaxel Top Patent Applicants

In summary, the market for Taxotere has been reasonably well protected by the innovator with a proactive patenting strategy. However, data exclusivity and molecule patent protection for Docetaxel in most of territories has now expired or will expire in the near future and the markets are showing signs of generic competition for at least part of the Taxotere product suite in some countries. With much taxane formulation technology in the public domain prior to the launch of Taxotere, the innovator relies mainly on the twin vial formulation patent protection to safeguard part of its market share for Docetaxel, as well as some protection of specific indications. In markets where only the twin vial system is authorised, this protection may represent and additional 2-3 years of monopoly unless the patents are successfully challenged.

This molecule demonstrates that the proactive use of comprehensive patent information will lead to higher returns from generic development by being first to market after molecule patent expiry. The rewards of being informed are much more satisfying than the cost of making an IP mistake, or simply being one of many other generics on the market. Generic developers are therefore strongly advised that a comprehensive search of the patent landscape around any product, particularly one as complex as Docetaxel is a crucial step before any technical development takes place.

This evaluation is based on the Pipeline Selector Core report, which can be extended to cover over 40 countries for a nominal fee. GenericsWeb Pipeline Selector reports are available for any active ingredient upon request. Comprehensive data for patent families relating to Docetaxel, based on professional patent searching, may be accessed by subscribing to the GenericsWeb Pipeline Developer report which include twelve monthly updates to keep you abreast of recently published patents and applications.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.